You are here: Industry Insights > rituximab

News List

Rituximab found to extend progression-free survival in indolent lymphoma pharmatimes
March 27, 2019
New trial results have been published showing that a combination of Celgene's Revlimid and Roche's rituximab (R2) significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placeb
The 1st Chinese-produced Biosimilar Approved for Marketing PharmaSources/Yuntian
March 20, 2019
We would find out the reason if we looked into the situation of the original drug of rituximab
ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL drugs
December 04, 2018
For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved.....
Sandoz to focus on more lucrative markets biospectrum
November 16, 2018
Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in the long term.
GSK trials Benlysta/rituximab combo for lupus pharmatimes
July 23, 2018
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
US widens scope of Rituxan to include life-threatening skin condition pharmatimes
July 10, 2018
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
US nod for Venclexta/Rituxan combo pharmatimes
July 10, 2018
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen's Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
NHS England clears specialised treatments for NHS use pharmatimes
July 10, 2018
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Novartis' biosimilar rituximab delayed in US pharmatimes
May 04, 2018
Novartis' Sandoz division announced today that the US FDA has issued a complete response letter regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab, meaning that approval of the drug has been delayed in the country.
GSK trials Benlysta/rituximab combo for lupus pharmatimes
March 23, 2018
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.

Previous page 1 2 3 Next page